Edoxaban: from data quality to safety in clinical practice
Reduced dosage, high efficacy and greater safety in the anticoagulant treatment of fragile patients
Edoxaban: from data quality to safety in clinical practice
Reduced dosage, high efficacy and greater safety in the anticoagulant treatment of fragile patients
At the 77th SIC national congress, a symposium was held, sponsored by Daiichi-Sankyo, on the characteristics of Edoxaban, the latest addition to the family of NAOs (New Oral Anticoagulants). Strengthened by the results of the Engage AF-TIMI 48 study, which involved over 21 thousand patients, segmented into different subgroups with specific needs, Edoxaban is proposed as an anticoagulant capable of personalising the dosage in non-valvular atrial fibrillation, attesting to high levels of efficacy and safety. Similar results are expected in the treatment of venous thromboembolism, based on the evidence that emerged following extensive in-depth analyses of the Hokusai study.
At the 77th SIC national congress, a symposium was held, sponsored by Daiichi-Sankyo, on the characteristics of Edoxaban, the latest addition to the family of NAOs (New Oral Anticoagulants). Strengthened by the results of the Engage AF-TIMI 48 study, which involved over 21 thousand patients, segmented into different subgroups with specific needs, Edoxaban is proposed as an anticoagulant capable of personalising the dosage in non-valvular atrial fibrillation, attesting to high levels of efficacy and safety. Similar results are expected in the treatment of venous thromboembolism, based on the evidence that emerged following extensive in-depth analyses of the Hokusai study.
full talks
La qualità degli studi e la robustezza dei dati nella fibrillazione atriale
it
Dr. Giuseppe di Pasquale
La sicurezza nei diversi contesti clinici del paziente con fibrillazione atriale
it
Dr. Roberta Rossini
Nuove evidenze dallo studio Hokusai: efficacia e sicurezza nel TEV
it
Dr. Andrea Fontanella
Edoxaban: dalla qualità dei dati alla sicurezza nella pratica clinica - Questions and Answers
it
activated factor X and virtual reality: interviews
Una nuova, preziosa arma nella prevenzione del trombombolismo v.
it
Prof. Salvatore De Rosa
Coagulazione: un farmaco intelligente per inibire il fattore Xa
it
Prof. Giuseppe Germanò
Il nuovo anticoagulante orale a lunga vita da assumere una volta al dì
it
Prof. Salvatore Novo
Sistemi multimediali per "vedere" l'azione contro i tromboembolismo
it
Dr. Michele A. Clemente
Perché un internista deve conoscere i farmaci antitrombotici
it
Dr. Maddalena Avella